Novartis reports strong Q2 2024 sales, with Kesimpta and Pluvicto showing significant growth. Learn more about NVSEF stock ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

" width="1200" height="675" /> JNVST Lateral Entry Admission 2025: Navodaya Vidyalaya Samiti has commenced registration for NVS Class 9 and the Class 11 lateral entry test 2025. Those eligible to ...

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The ...

The Dividend History page provides a single page to review all of the aggregated Dividend payment information. Visit our Dividend Calendar: Please note that the dividend history for Nasdaq stocks ...

Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical company that specializes in innovative drugs across key areas like oncology, rare diseases, neuroscience, and cardio-metabolic ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

Candidates have time till September 23 to fill the applications for Jawahar Navodaya Vidyalaya Selection Test.

The last date of registration for the Jawahar Navodaya Vidyalaya Selection Test (JNVST) 2025 has been extended. Interested ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...